XSHE
200028
Market cap1.59bUSD
Jul 10, Last price
11.67HKD
1D
0.09%
1Q
-16.64%
Jan 2017
-67.37%
Name
China National Accord Medicines Corp Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
China National Accord Medicines Corporation Ltd. focuses on the distribution of medical supplies and pharmaceuticals. Its broad product range encompasses traditional Chinese, biochemical, biological, and diagnostic medicines, as well as antibiotics and chemical preparations. The company also trades in food products, industrial chemicals, various general commodities, medical apparatus and instruments, glassware, cosmetics, daily merchandise, and offers wholesale and retail of health products. In addition to product sales, it provides a suite of services, including freight transportation, warehousing, loading and unloading, professional consultation, goods agency, technology import and export, and property leasing. As of December 31, 2021, the company operated a significant retail network of 8,798 drugstores, consisting of 7,257 directly owned and 1,541 franchised outlets, spanning 20 provinces, autonomous regions, and municipalities across China. Founded in 2004 and headquartered in Shenzhen, China, this entity functions as a subsidiary of Sinopharm Group Co., Ltd.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||